Kurt. no on everyone. an among have currently approved start These to update are of to and lung late need stage our Thanks, non-small-cell options. of treatment development physicians mutations in Hello, the the treat in is focused difficult investigating patients The going Exon cancer. by poziotinib. program mutation on exon XX asset insertion most FDA are their I'm pozi effective providing therapy. XX and treatment
HERX XX QX. the mentioned, X which in results is evaluating full insertion pozi from mutations. cohort expect in Joe is cohort top reached in with enrollment treated patients quarter. This patients previously previously line EGFR evaluating Cohort As the treated we fourth exon X,
ahead was schedule happened six This speaks medical of as clear milestone months exciting it to unmet an needs. and the
the mutation. actively X treatment and patients while that previously X are HERX data. with requests at cancer Cohort this numerous HerX X, and in trial cohorts address includes insertion We EGFR enrolled both patient open We us patients. are with first ZENITHXX there's because EGFR cohorts been in or non-small-cell exon generate cohort the lung enter fully naive X. to XX helps or mutation. our these and cohort continuing treatment treated to We three looking requests useful This announced recruiting insertion recently exon X pleased XX cohorts line with and enrollment additional
in are which preclinical recruiting. at Anderson. is Dr. activity. transmembrane cellular resistant therapy. treatment lung we preclinical vitro way, no non-small-cell EGFR presented domains EGFR X effective Heymach's World cohorts and Cohort with you non-small-cell Recent develop poziotinib mechanism. supporting tumor extra have many new the common variety the X while includes group dependent the cancer on there Lung osimertinib XX-XX, for and or against of first-line the mutations. may Cohort from HERX exons be of in By EGFR poziotinib And or actively and suggests progress that mutation a includes All cohorts new by patients strong X will in see evidence of cancer data three upcoming less whose with MD patient lung these meeting active Barcelona, X data
clinical demonstrating Now, which duration with shifting severe patients. poster pivotal studies included XXX data from was the neutropenia. integrated total of reduction from integrating pegfilgrastim to of both a in ROLONTIS, at ASCO, consistent results we individual our was three analysis efficiency safety to presented non-inferior ROLONTIS of that phase The of a and of ROLONTIS trials, the the
file, fourth Based to that we a expectation submit around to had the the in recently manufacturing. our the the quarter outcome productive meeting, which focused the FDA with meeting module on we of further module is on expect Regarding this BLA year. three, BLA of discuss their
I FIT is enter the a acquired area the with the associated of know historically work as addition invalidated fusing shift a space, on creates This cancer by been Now, has biotherapeutics let toxicity. immuno-oncology new an FIT and antibody technology to platform. FIT well. tumor very therapeutics, monoclonal that we platform newly engineered are data a interferon welcome have to the a as minimize specific well to me established The alpha cytokines class pipeline our potential but side Interferons Preclinical systemic maintain potent with targeting antigen. effects. that that the are suggest efficiency significant
see, about As on goals balanced well you and the we have can The path is team our pipeline. energized growing our and a executing forward.
Joe. to back it turn I'll Now,
